Table 2.
Cox Regression Analysis of HPV 16/18 DNA and FOXM1 Expression with OS and RFS of Patients with Cancer.
| Variables | Oral Cancer (n = 110) |
Variables | Lung Cancer (n = 117) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | OS |
RFS |
No. | OS |
RFS |
||||||||||
| Median Survival (Months) | HR (95% CI)⁎ | P | Median Survival (Months) | HR (95% CI)⁎ | P | Median Survival (Months) | HR (95% CI)⁎ | P | Median Survival (Months) | HR (95% CI)⁎ | P | ||||
| HPV 16/18 DNA | HPV 16/18 DNA | ||||||||||||||
| Negative | 51 | 33.3 | 1 | 25.5 | 1 | No | 55 | 30.7 | 1 | 25.5 | 1 | ||||
| Positive | 59 | 23.1 | 0.92 (0.49-1.74) | .810 | 19.9 | 1.40 (0.78-2.51) | .259 | Yes | 62 | 21.5 | 1.43 (0.88-2.34) | .148 | 20.7 | 1.85 (1.12-3.03) | .015 |
| FOXM1† | FOXM1† | ||||||||||||||
| Low | 62 | 32.5 | 1 | 25.5 | 1 | Low | 46 | 35.3 | 1 | 30.3 | 1 | ||||
| High | 48 | 22.2 | 4.70 (2.50-8.87) | < .001 | 16.6 | 2.84 (1.60-4.95) | < .001 | High | 71 | 18.2 | 1.74 (1.06-2.86) | .030 | 13.6 | 1.97 (1.23-3.14) | .004 |
| HPV 16/18 DNA†/FOXM1 | HPV 16/18 DNA/FOXM1 protein† | ||||||||||||||
| Negative/low | 33 | 25.6 | 1 | 25.5 | 1 | Negative/low | 34 | 35.3 | 1 | 33.3 | 1 | ||||
| Positive/low | 29 | 42.3 | 0.16 (0.04-0.70) | .015 | 29.5 | 0.57 (0.20-1.64) | .299 | Positive/low | 12 | 39.4 | 0.45 (0.13-1.59) | .214 | 29.7 | 0.53 (0.18-1.53) | .241 |
| Negative/high | 18 | 38.8 | 2.73 (1.19-6.29) | .018 | 35.2 | 2.56 (01.17-5.64) | .019 | Negative/high | 21 | 30.9 | 0.94 (0.43-2.03) | .870 | 15.4 | 1.06 (0.50-2.26) | .880 |
| Positive/high | 30 | 15.1 | 3.71 (1.46-9.41) | .006 | 20.0 | 3.43 (1.47-8.00) | .004 | Positive/high | 50 | 17.8 | 1.76 (1.02-3.05) | .043 | 12.9 | 2.35 (1.37-4.03) | .002 |
CI, confidence interval.
⁎
HR adjusted for age, gender, smoke, tumor type, and stage.
†
HPV 16/18 DNA in tumors was detected by nested PCR, and the data were obtained from our previous reports.